Ying Feng
Head of Biology Small Molecules

Ying brings 25 years of pharmaceutical experience with a focus on small molecule drug development for cancer and rare diseases.

Prior to joining NysnoBio, Ying was Associate Director at Vivace Therapeutics, responsible for pharmacological evaluation of small molecule drug candidates targeting Hippo-YAP pathway for cancer indication. Before Vivace, she worked at LEAD Therapeutics from 2008–2010, and was a major contributor to the discovery of the PARP inhibitor Talazoparib, which was acquired by BioMarin Pharmaceutical in 2010. Ying then joined BioMarin where she served as senior Scientific Manager, and managed a large part of the translational research of Talazoparib (compound MOA, PK/PD/efficacy, drug combination, biomarker discovery, etc.), supporting IND filing and subsequent clinical development, until Talazoparib was sold to Medivation by BioMarin (Talazoparib gained FDA approval in 2018). In addition, she led and supported several other drug discovery projects for rare diseases during her 8 years at BioMarin.

In her earlier career, Ying worked at Scios/Johnson & Johnson for 12 years, where she held positions with increasing responsibilities and led a research bioassay group to support multiple drug development projects, including 2 IND candidates.

Ying has a BS in biochemistry from Wuhan University, and MS in immunology from Case Western Reserve University School of Medicine in Cleveland, Ohio. She has co-authored 17 peer-reviewed papers and is a co-inventor on 3 patents.